Consistent with our previous study [45], these observations suggest that clinically obtained MVV, PLT, Hb and severity of illness are the key factors for using the XGBoost model to predict pulmonary function status in COVID-19 survivors. The gene discussed is GSTM1; the disease is COVID-19.